The Changing Treatment Paradigm for Prolactinoma—A Prospective Series of 100 Consecutive Neurosurgical Cases
Authors' conclusion
High remission rates were achieved, improving HR-QoL, demonstrating (repeat) prolactinoma surgery is effective in an experienced pituitary center, as highlighted in the most recent guideline (2023).
Study context
- Population
- Consecutive patients with prolactinoma undergoing surgery, January 2021–August 2023; 72 female; DA intolerance most frequent indicationconsecutive surgical cases · DA intolerance most frequent indication 68
- Participants
- 100 / 78 / 52 / 9
- Exposure
- All vs Elective total resection vs High-probability first total resection vs Reoperations
- Alln = 100
- Elective total resectionn = 78
- High-probability first total resectionn = 52
- Reoperationsn = 9
- Outcome
- Remission after elective total resection
Methodological detailsconsecutive patients, single-centre, Follow-up median, 15.0 [10.0-24.8 months]
- Consecutive patients
- Single-centre
- Follow-up median, 15.0 [10.0-24.8 months]
Main finding
As reported in the abstract
- Surgical goal (debulking/total resection) achieved
- 90%
Observational data: associations, not effects.
Further findings
Leiden Bothers and Needs Pituitary Total Bothers score, change after surgery
- Total Bothers score improved significantly after surgery: Δ (IQR −14.4 to −0.9), P < .001
- −3.4
Leiden Bothers and Needs Pituitary Total Needs score, change after surgery
- Total Needs score improved significantly after surgery: Δ (IQR −11.9 to 1.3), P = .006
- −1.8
Safety
- Long-term complications — All
- 4%
Original publication
The Changing Treatment Paradigm for Prolactinoma—A Prospective Series of 100 Consecutive Neurosurgical Cases. J Clin Endocrinol Metab. Published 18 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →